130 related articles for article (PubMed ID: 12376032)
1. Comparative killing rates of gatifloxacin and ciprofloxacin against 14 clinical isolates: impact of bacterial strain and antibiotic concentration.
Pendland SL; Neuhauser MM; Garey KW; Prause JL; Jung R
Diagn Microbiol Infect Dis; 2002 Sep; 44(1):59-61. PubMed ID: 12376032
[TBL] [Abstract][Full Text] [Related]
2. Activity of gatifloxacin and ciprofloxacin in combination with other antimicrobial agents.
Gradelski E; Kolek B; Bonner DP; Valera L; Minassian B; Fung-Tomc J
Int J Antimicrob Agents; 2001 Feb; 17(2):103-7. PubMed ID: 11165113
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.
Otani T; Tanaka M; Ito E; Kurosaka Y; Murakami Y; Onodera K; Akasaka T; Sato K
Antimicrob Agents Chemother; 2003 Dec; 47(12):3750-9. PubMed ID: 14638477
[TBL] [Abstract][Full Text] [Related]
4. Comparative antimicrobial activity of gatifloxacin with ciprofloxacin and beta-lactams against gram-positive bacteria.
Bassetti M; Dembry LM; Farrel PA; Callan DA; Andriole VT
Diagn Microbiol Infect Dis; 2001 Nov; 41(3):143-8. PubMed ID: 11750168
[TBL] [Abstract][Full Text] [Related]
5. Susceptibility of bacterial isolates to gatifloxacin and ciprofloxacin from clinical trials 1997-1998.
Huczko E; Conetta B; Bonner D; Valera L; Stickle T; Macko A; Fung-Tomc J
Int J Antimicrob Agents; 2000 Dec; 16(4):401-5. PubMed ID: 11118848
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of difloxacin against canine bacterial isolates.
van den Hoven R; Wagenaar JA; Walker RD
J Vet Diagn Invest; 2000 May; 12(3):218-23. PubMed ID: 10826834
[TBL] [Abstract][Full Text] [Related]
7. Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test.
Madhusudhan KT; Counts C; Lody C; Carter O; Dodson S; Ojha N
Chemotherapy; 2003 Jul; 49(4):184-8. PubMed ID: 12886053
[TBL] [Abstract][Full Text] [Related]
8. Comparative in vitro potency of gemifloxacin and fluoroquinolones against recent European clinical isolates from a global surveillance study.
Hoban DJ; Bouchillon SK; Johnson JL; Zhanel GG; Butler DL; Miller LA; Poupard JA;
Eur J Clin Microbiol Infect Dis; 2001 Nov; 20(11):814-9. PubMed ID: 11783700
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
Zhanel GG; Roberts D; Waltky A; Laing N; Nichol K; Smith H; Noreddin A; Bellyou T; Hoban DJ
J Antimicrob Chemother; 2002 May; 49(5):807-12. PubMed ID: 12003975
[TBL] [Abstract][Full Text] [Related]
10. Moxifloxacin activity against clinical isolates compared with the activity of ciprofloxacin.
Aktaş Z; Gönüllü N; Salcioğlu M; Bal C; Anğ O
Int J Antimicrob Agents; 2002 Sep; 20(3):196-200. PubMed ID: 12385698
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of gatifloxacin, a new fluoroquinolone, against 204 anaerobes compared to seven other compounds.
Dubreuil L; Behra-Miellet J; Neut C; Calvet L
Clin Microbiol Infect; 2003 Nov; 9(11):1133-8. PubMed ID: 14616733
[TBL] [Abstract][Full Text] [Related]
12. Comparative bactericidal activity of fluoroquinolones against clinical isolates resistant to fluoroquinolones.
Drago L; De Vecchi E; Nicola L; Valli M; Marchetti F; Gismondo MR
J Chemother; 2003 Apr; 15(2):118-23. PubMed ID: 12797386
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
Malmborg AS; Ahlén S
Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030
[TBL] [Abstract][Full Text] [Related]
14. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.
Montanari MP; Prenna M; Mingoia M; Ripa S; Varaldo PE
Chemotherapy; 1998; 44(2):85-93. PubMed ID: 9551237
[TBL] [Abstract][Full Text] [Related]
15. Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections.
Pfaller MA; Jones RN
Diagn Microbiol Infect Dis; 2002 Sep; 44(1):77-84. PubMed ID: 12376036
[TBL] [Abstract][Full Text] [Related]
16. Bacterial eradication by clinafloxacin, CI-990, and ciprofloxacin employing MBC test, in-vitro time-kill and in-vivo time-kill studies.
Cohen MA; Huband MD; Yoder SL; Gage JW; Roland GE
J Antimicrob Chemother; 1998 Jun; 41(6):605-14. PubMed ID: 9687098
[TBL] [Abstract][Full Text] [Related]
17. In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin.
Cohen MA; Huband MD; Gage JW; Yoder SL; Roland GE; Gracheck SJ
J Antimicrob Chemother; 1997 Aug; 40(2):205-11. PubMed ID: 9301985
[TBL] [Abstract][Full Text] [Related]
18. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study.
Hoban DJ; Bouchillon SK; Johnson JL; Zhanel GG; Butler DL; Miller LA; Poupard JA;
Diagn Microbiol Infect Dis; 2001; 40(1-2):51-7. PubMed ID: 11448564
[TBL] [Abstract][Full Text] [Related]
19. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.
Kowalski RP; Dhaliwal DK; Karenchak LM; Romanowski EG; Mah FS; Ritterband DC; Gordon YJ
Am J Ophthalmol; 2003 Sep; 136(3):500-5. PubMed ID: 12967804
[TBL] [Abstract][Full Text] [Related]
20. [In vitro activity of trovafloxacin (CP-99,219) against 434 bacterial strains: comparative study with other fluoroquinolones].
Tali-Maamar H; Tebbal S; Rahal K
Arch Inst Pasteur Alger; 1998; 62():52-61. PubMed ID: 11256319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]